Transcript Document

European Priorities for Global Health
Research
BIO International Convention
Washington, 27-30 June 2011
Dr. Andrzej Jan Rys
Director \
Health systems and products
Directorate General for Health and Consumers
European Commission
Overview
Health research supporting the aims of Europe
2020: the ‘Innovation Union’
• FP7 projects
• Innovative Medicines Initiative
• Joint programming
• Innovation in health
• Health workforce
systems
• Mental health
• Health Technology
Assessment
• European Innovation
Partnership on Active and
Healthy Ageing
• Climate change
• Young health workers
Resource
efficient Europe
• Youth at risk of exclusion
Adopted 26/1/2011
Agenda for new
skills and jobs
Youth on the
move
Adopted 23/11/10
Adopted 15/09/10
Innovation
union
Adopted 06/10/10
Health in
Europe 2020
European platform
against poverty
Adopted 16/12/10
• eHealth, ICT
Digital agenda
for Europe
Industrial policy for
globalisation era
Adopted 28/10/10
• Mental health
• Health inequalities
• Active and healthy
Adopted 19/05/10
• Pharmaceuticals
• Medical devices
Health for smart, sustainable and inclusive
growth
ageing
• Access to healthcare
• Health promotion
(e.g. tobacco)
Europe 2020 strategy – the innovation union one of seven
flagship initiatives:
To improve framework conditions and access to finance for research and
innovation so as to ensure that innovative ideas can be turned into products and
services that create growth and jobs.
Focussing on societal challenges: e.g. climate change, energy and resource
efficiency, health and demographic change. Strengthening links in the innovation
chain.
By:
Completing ERA, developing a strategic research agenda focused on challenges
including health and ageing
Improving framework conditions for business to innovate
Creating 'European Innovation Partnerships' between the EU and national levels to
speed up the development and deployment of the technologies needed to meet the
challenges identified.
FP7 Health Programme
• Main policy drivers:
• Improving health of European citizens
• Increasing competitiveness of European health-related
industries and businesses
• Addressing global health issues
The Co-operation programme
The Health Theme
Three main activities (“pillars”)
Activity 1:
Biotechnology,
generic tools
& technologies
for health
Activity 2:
Activity 3:
Translating
research for
human health
Optimising
the delivery
of health care
cross-cutting issues: international cooperation, SMEs,
child health, ageing populations, gender-related health issues
Activity 4: Support actions & response to policy needs
FP7 Health Theme Results to date
• 433 contracts signed (Jan. 2010):
•
4 574 participants  566 SMEs (~11%)
•
EU contribution ~ € 1.8 billion
The Innovative Medicines Initiative (IMI):
the largest PPP in life sciences R&D
Why apply?
•
Looking for additional funding
•
Interested in patient-centric biomedical/pharmaceutical research
•
Interested in collaborating with large pharmaceutical companies
Key concepts
•
Non-competitive research for EFPIA companies
•
Competitive calls for IMI beneficiaries
•
Open collaboration in final consortia
Step 1:
Pharma 1
Pharma 2
Pharma 3
Building an
IMI consortium
Pharma 4
Pharma 6
Pharma 5
A set of EFPIA
companies
define a topic
on which they
commit to
collaborate
Step 2:
Acad 1
Patients’
Organ 1
Acad 2 Acad 3
Acad 4
Patients’
Organ 2
Regul 1
SME 1
Consortia eligible for EU funding compete
through Expressions of Interest which are
ranked by independent experts
SME 2
Step 3:
Other*
Acad 1
Acad 2
Acad 3
Pharma 1
Patients’
Organ 1
Patients’
Organ 2
Acad 4
Regul 1
Pharma 3
SME 1
SME 2
Pharma 4
Pharma 6
Pharma 5
Other*
Pharma 2
The top-ranked EUfundable consortium
joins the EFPIA
companies to form the
final consortium
which develops the full
proposal, subject to
peer-review before final
approval
Eligibility for IMI JU funding
•
Eligible for funding
•
•
•
•
•
•
Not eligible for funding
•
•
•
•
Academia
SMEs (EU definition)
Patients’ Organisations
Non-profit research organisations
Intergovernmental organisations
EFPIA companies (in kind contribution)
Companies that fall outside the EU definition of SMEs
Others
IMI funds activities in the EU + FP7 associated countries
The 4th Call for Proposals:
key features
•
First ‘Think Big’ topics (± €50 million total budget per topic)
• European Medical Information Framework (± €50 million)
• Induced pluripotent stem cells (± €50 million)
•
In addition, new research areas in pharmaceutical chemistry, oral drug
delivery, binding kinetics, optimising delivery of biological macromolecules
will be addressed
•
The topics will continue to bring together data, resources and expertise
from the public and private sectors to improve pharmaceutical research
Call 4 topics (indicative)
Medical Information System
1. A European Medical Information Framework (EMIF) of patient-level data to
support a wide range of medical research
2. eTRIKS: European translational information and knowledge management
services
Chemistry, Manufacturing and Control
3. Delivery and targeting mechanisms for biological macromolecules
4. In vivo predictive biopharmaceutics tools for oral drug delivery
5. Sustainable chemistry – delivering medicines for the 21st century
Technology and Molecular Disease Understanding
6. Human induced pluripotent stem (hiPS) cells for drug discovery and safety
assessment
7. Understanding and optimising binding kinetics in drug discovery
Call 4 timeline (indicative)
• Open Info Day: 17 June 2011
• Official launch: End June 2011
• Deadline for submission of Expression of Interests: End October
2011
• Peer review evaluation: November 2011
• Deadline for submission of Full Project Proposals: March 2012
• Approval of Full Project Proposals: May 2012
5-years (2003-2007) average
number of biotechnology patent
applications to the EPO
Germany
850,3537
France
388,4246
United Kingdom
Netherlands
245,4441
Denmark
183,1758
Italy
147,3154
Belgium
131,6968
Sweden
105,8776
Spain
85,11676
Austria
83,0294
Finland
40,53952
Ireland
14,95716
Poland
8,1912
Portugal
7,84774
Hungary
6,89238
Czech Republic
5,79492
Greece
(measured by inventor's country of residence, on
100 000 inhabitants; source: OECD)
359,499
5,71
Slovenia
4,58286
Estonia
3,05438
Bulgaria
1,719867
Lithuania
1,640625
Luxembourg
1,20666
Slovak Republic
1,05554
Cyprus
1
Malta
1
Romania
Latvia
0,6631
0,657725
Number of biotechnology patent applications to the EPO in Poland, 2003-2007
Poland
14
12,7333
Bio patents
12
10
8
Poland
6,7143
6
4
9,0167
8,0667
4,425
2
0
2003
2004
2005
2006
2007
Years
(measured by inventor's country of residence, on 100 000 inhabitants; source: OECD)
R&D expenditure as % of GDP, 1999-2009
2,50%
2,00%
1,50%
European Union (27 countries)
Poland
1,00%
0,50%
0,00%
1999
2000
2001
2002
2003
2004
2005
2006
2007
(source: Eurostat)
2008
2009